EuroMedtech™ 2012 Program Overview

To supply a significant unmet need with a disruptive technology is the goal of every emerging medtech company. But commercializing that technology requires skill sets far removed from the initial eureka moment. In-depth market knowledge, establishment of long term relationships, and navigation of multiple reimbursement systems are only a few of the requisite hurdles facing an emerging company. This workshop will explore how to determine the right commercialization strategy for your company, how to develop necessary relationships with key opinion leaders and partners, and why commercialization and reimbursement strategies need to be developed together. Practical examples will be provided by young companies as well as insights from established medtech leaders about what makes some emerging companies stand out from the crowd.

Moderator:
Raman Minhas – CEO, ATPBio

Panelists:

• John Icardi – Partner, TCG Consulting
• Sofia Ioannidou – Associate, Edmond de Rothschild Investment Partners
• Chris Jones – CEO, GlySure

EuroMedtech™ 2012

You have your product. You've done your market research, you've connected with KOLs, you have the financing. Now it's time to sell. As exits appear more remote than ever, young companies are having to set up structures and gain expertise in areas that they previously would not have had to consider, especially when it comes to sales and distribution. How does a company decide what sales model to adopt in order to get its products to its target market? What in-house expertise needs to be developed? Do different approaches need to be adopted for international markets? And would certain approaches make a company more attractive for potential acquirers? This panel will explore the options available to companies and the considerations that drive this decision.

Moderator:
Tina Tan – Editor, Clinica Medtech Intelligence

Panelists:

• Trevor Dekker – Head, Sales and Marketing, JenaValve
• Jon H. Hoem – CEO, Miracor Medical Systems GmbH
• Jason Loveridge – CEO, Parvulus
• Guy Mansart – Commercial Director, Minitubes

EuroMedtech™ 2012

It is a perennial question: is growth fueled by start-ups with disruptive technologies or large acquisitions? And does growth necessarily go hand in hand with innovation? This panel will examine the sources of medtech innovation and how these contribute to growth within the medtech sector. Does a high level of innovation give start-ups an edge or does the lack of exits reflect a higher bar in a difficult market? Will new players and technologies which identify unmet medical needs, especially through involvement in the ICT sector and the increasing involvement of the public sector, result in a different business model within the medtech space to accommodate these shifts? Representatives from medtech players old and new will give their perspectives on how current trends help them identify sources of innovation and how these new developments are changing the way they operate in the medtech industry.

Moderator:
Regina Hodits – General Partner, Wellington Partners

Panelists:

• Angelo De Rosa – Senior Director, Strategy and Business Development, Europe, Middle East, Africa and Canada, Medtronic
• Charles Knowles – Clinical Professor, Surgical Research and Hon. Consultant Colorectal Surgeon, Centre for Digestive Diseases, Queen Mary University London
• Josep Ll. Sanfeliu – Partner, Ysios Capital Partners

EuroMedtech™ 2012

With healthcare systems the world over under increasing strain, it remains to be seen if telehealthcare technologies will become the panacea they once promised. Providing a way forward for patient-focused care, alleviating workflow pressure and improving system flexibility, telehealthcare still has to develop a business model that makes sense for companies, investors and payors. While many pilot studies have proven the effectiveness of products, incentives for investment or adoption are often misaligned, prompting some companies to adopt consumer-based approaches to market entry. Non-traditional players are increasingly entering the healthcare sector through the telehealthcare avenue and bringing with them business models from other sectors that could gain traction in this space. Pioneered by health and fitness products, consumer telehealthcare tools now extend from gaming that aids injury rehabilitation to home administered ECGs. With patients assuming ever more control over their own health management, can and should healthcare services stimulate systemic adoption through pre-commercial procurement initiatives? Should companies forge ahead by further developing a consumer-based sales model? How would either of these models impact the development strategies undertaken by emerging telehealthcare companies? And which model would ensure that this new sector fulfills its possibilities?

Moderator:
Thom Rasche – Partner, Earlybird Venture Capital

Panelists:

• Marc Attia – Founder and VP, Sales and Marketing, Movea
• Erwann Binet – VP, Economic Development and Innovation, Conseil general de l'Isere
• Patrick Blouet – Corporate Partnerships and Public Affairs Manager, ST-Ericsson
• Elena Bonfiglioli – Senior Director Health Industry, Europe Middle East and Africa, Public Sector, Microsoft

EuroMedtech™ 2012

While SMEs the world over face common hurdles in getting a medtech product on the market, all geographies are not created equal. Lingering uncertainty over regulatory developments in the US, a volatile economic outlook in Europe and navigating the unknown in Asia all impact where, when and how companies launch their products. Lately, Europe has been hailed as the preferred starting point for US companies, with some companies going so far as to establish themselves in the EU and forgo initial operations in the US. But with calls for greater regulatory coordination within Europe due to events such as the recent highly publicized PIP recall, continued criticism of the FDA over unclear direction, and attempts in Asian markets to jump start internal innovation, the fine line the regulatory agencies tread between patient safety and fostering innovation is under greater scrutiny than ever before. How can companies negotiate different regulatory systems efficiently? What unique features of each regulatory area foster business and which create additional hurdles for companies? And how will upcoming changes to the different systems affect how SMEs interact with regulatory bodies?

Moderator:
Shayesteh Fürst-Ladani – Managing Director, SFL Regulatory Affairs & Scientific Communication Ltd

Panelists:

• Claudia Graeve – Medical Affairs and Technology Director, Anteis SA
• Corinne Lebourgeois – Managing Director, MedC. Partners

EuroMedtech™ 2012

Incremental innovation in orthopedics has become the norm. So where can doctors and patients expect breakthrough technologies to emerge? Will the evolution of ICT in healthcare settings result in a completely new source of innovation? Has the time come when innovation in procedure will overshadow innovation of new materials? With software being developed to assist in hip resurfacing and micro and nano surgical imaging techniques allowing for greater precision, has a fundamental shift been taken in orthopedics?

Moderator:
Mehdi Tavakoli – Professor; Technical Director, HealthTech and Medicines Knowledge Transfer Network, TWI Ltd

Panelists:

• Anthony Boyer – President and CEO, Blue Ortho
• Simon Donell – Consultant Orthopaedic Surgeon, Norfolk & Norwich University Hospital
• Paula Gomes – Global Medical Technology Practice, Cambridge Consultants

EuroMedtech™ 2012

Diagnostic companies have been tapped to play a key role in creating a more patient-centric healthcare system while lowering costs through increased efficiency. The development of molecular diagnostics means patients can expect personalized therapies, and the increasing ease of point-of-care diagnostics through telehealthcare advances means deliverable results quicker and in a variety of new settings. This progress has resulted in the need for new collaborations between players who have traditionally been divided from each other by differing incentives, values chains, and areas of operation. How will the emergence of a health-outcomes ecosystem change the kinds of partnerships developed by diagnostic companies and how will these collaborations translate into improved care for patients?

Moderator:
Reinhard Merz – Director, European Operations, TCG

Panelists:

• Jean Deleforge – Senior Corporate VP, Molecular Unit, bioMérieux
• Frédéric Eberlé – Medical Manager, Roche Diagnostics
• Nadia Plantier – Director, External Collaborations and Business Development, ImmunID

EuroMedtech™ 2012

Device innovation is usually seen as the ultimate goal in medical technology development. A different kind of innovation could potentially be the key to more efficient, safer and personalized healthcare delivery. Combining new technologies with procedural innovations may not cause the excitement in the industry and investment community that major product innovations do, but they can have just as positive and dramatic an impact on patients and practitioners. The phrase "augmented medicine" is often used to describe this collision of new technologies and procedures and the OR is one of the major arenas where this combination occurs. Often centered on improving surgical navigation, both in reality and in surgeon training, and utilizing cutting edge ICT imaging tools and surgical robotics, these procedural innovations are revolutionizing the OR of the future. What are the new developments in the area? Are there specific hurdles that companies in this growing area are facing in reaching the market? And how can augmented medicine deliver improved healthcare outcomes?

Moderator:
Sigal Weisswasser – President and CEO, The T.B.N. Group

Panelists:

• Alim Louis Benabid – Chairman of the Board, CEA Clinatec
• Rubi Halberthal – Chairman and Co-Founder, Haldor Advanced Technologies
• Clement Vidal – CEO, EndoControl

EuroMedtech™ 2012

Pioneered in Grenoble for movement disorders, Deep Brain Stimulation (DBS) is now an established treatment for indications such as Parkinson's disease and dystonia. However, it remains a last resort treatment for other indications such as psychiatric disorders, chronic pain and obesity. New indications could result in a great leap in DBS applications; completely new approaches, such as deep TMS and micro/nanotechnology advances, have expanded the possibilities of neuromodulation applications. Which treatment method holds the greatest promise of success? What hurdles would need to be overcome to ensure a wider adoption of DBS and other neuromodulation therapies as front line treatments? Are the practical limits of qualified surgeons and the high cost of devices in comparison to non-surgical interventions hampering adoption? Will less invasive treatments such as deep TMS or more accurate devices allow greater adoption of DBS for new indications? This panel will feature cutting edge researchers and industry experts leading the field in neuromodulation applications.

Panelists:

• Stéphan Chabardes – Professor of Neurosurgery; Head, Functional Neurosurgery and Neuro-oncology Unit, Clinique de Neurochirurgie CHU de Grenoble
• Sjaak Deckers – CEO, Sapiens
• Karl Schweitzer – VP, Medtronic Neuromodulation, Western Europe and Canada

EuroMedtech™ 2012